OBJECTIVES: To review the published literature of the past 15 years regarding use of calcium channel blockers (CCBs) in psychiatric practice. These drugs, especially verapamil, have been recommended as possible treatments for mania and other disorders. METHODS: The Cumulative Medical Index and other databases were searched and back-tracked to locate relevant articles. Sixty-one such articles were uncovered: 37 anecdotal reports, 7 partially controlled reports, and 17 controlled trials. RESULTS: Most studies involved treatment of mania using verapamil. Although anecdotal reports were generally favourable, results from partially controlled reports or controlled clinical trials were mixed. Generally, verapamil was less effective than was lithium or placebo. Treatment of depression with CCBs was not very successful, regardless of the type of trial; the best trial was negative. The same was true for the treatment of schizophrenia, although the cases studied were extremely chronic and treatment-resistant. Evidence for efficacy in other illnesses, such as Alzheimer's disease or tardive dyskinesia was scanty but suggested that further trials might be in order. CONCLUSIONS: CCBs do not at present have an established place in psychiatric treatment. Nonetheless, clinicians faced with a manic patient not responsive to other antimanic drugs, either alone or in combination, might consider adding verapamil as an adjunct. A study bearing on this specific issue is needed to determine whether or not such off-label use would really be justified.
OBJECTIVES: To review the published literature of the past 15 years regarding use of calcium channel blockers (CCBs) in psychiatric practice. These drugs, especially verapamil, have been recommended as possible treatments for mania and other disorders. METHODS: The Cumulative Medical Index and other databases were searched and back-tracked to locate relevant articles. Sixty-one such articles were uncovered: 37 anecdotal reports, 7 partially controlled reports, and 17 controlled trials. RESULTS: Most studies involved treatment of mania using verapamil. Although anecdotal reports were generally favourable, results from partially controlled reports or controlled clinical trials were mixed. Generally, verapamil was less effective than was lithium or placebo. Treatment of depression with CCBs was not very successful, regardless of the type of trial; the best trial was negative. The same was true for the treatment of schizophrenia, although the cases studied were extremely chronic and treatment-resistant. Evidence for efficacy in other illnesses, such as Alzheimer's disease or tardive dyskinesia was scanty but suggested that further trials might be in order. CONCLUSIONS: CCBs do not at present have an established place in psychiatric treatment. Nonetheless, clinicians faced with a manicpatient not responsive to other antimanic drugs, either alone or in combination, might consider adding verapamil as an adjunct. A study bearing on this specific issue is needed to determine whether or not such off-label use would really be justified.
Authors: Julia C Bartsch; Pawel Fidzinski; Jojanneke H J Huck; Heide Hörtnagl; Richard Kovács; Agustin Liotta; Josef Priller; Christian Wozny; Joachim Behr Journal: Neuropsychopharmacology Date: 2014-10-15 Impact factor: 7.853
Authors: Michele L Ulrich; Susan Rotzinger; Sheila J Asghar; Paul Jurasz; Veronique A Tanay; Susan M J Dunn; Marek Radomski; Andy Greenshaw; Peter H Silverstone Journal: J Psychiatry Neurosci Date: 2003-03 Impact factor: 6.186
Authors: Greer S Kirshenbaum; Steven J Clapcote; Steven Duffy; Christian R Burgess; Janne Petersen; Karolina J Jarowek; Yeni H Yücel; Miguel A Cortez; O Carter Snead; Bente Vilsen; John H Peever; Martin R Ralph; John C Roder Journal: Proc Natl Acad Sci U S A Date: 2011-10-24 Impact factor: 11.205